Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K antagonist oral anticoagulants (NOACs) for the treatment and secondary prophylaxis of VTE is addressing the need for more-convenient alternatives to current standards of care, and these agents will drive market growth during the forecast period. However, considerable areas of unmet need exist within the VTE space, such as primary prophylaxis of VTE in acute medically ill patients and management of VTE treatment and risk in cancer patients. The ongoing label expansion program for NOACs and the anticipated launch of new therapies such as IONIS-FXIRx offer potential solutions to these unmet needs.
- How do the different VTE subpopulations contribute to the overall VTE market landscape? What will be the key drivers and deterrents for the VTE market during the 2017-2027 forecast period?
- How will uptake of newer agents in the market impact current market-leading therapies? Which agents will be the most successful and why?
- What do thought leaders think of the label expansion programs for NOACs? How do physicians perceive betrixaban, a new NOAC on the market, for managing medically ill patients?
- Which patient subpopulations have the greatest unmet need and commercial potential? Which drugs under development will fulfill these unmet needs?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought leaders in the field.
Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.
Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.
Emerging therapies: Phase II: 3 drugs; Phase III: 3 drugs. Coverage of select preclinical and Phase I products.
Shreya Saxena, M.B.A.
Shreya Saxena, M.B.A., is a senior business insights analyst on the Cardiovascular, Metabolic, and Renal Disorders team at DRG, part of Clarivate. Prior to joining DRG, she was a business analyst at the research firm Evalueserve. She obtained her M.B.A. with specializations in marketing and human resources and her bachelor’s degree in pharmacy from GGSIPU University in Delhi, India.
Ema Rodrigues, D.Sc., M.P.H.
Ema Rodrigues, D.Sc., M.P.H., is an epidemiologist with expertise in forecasting incident and prevalent populations in oncology and cardiovascular indications. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degrees (M.P.H., D.Sc.) in environmental health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes, including central nervous system cancer, cognitive function, and birth outcomes.